Triamterene

Triamterene in combination with HCTZ increases dofetilide AUC by 30%, Cmax by 16%, with pharmacodynamic effects increased by 190% (QTc increase over time). Concomitant use is contraindicated.

Concomitant use can produce severe hyperkalemia. Contraindicated.

Concomitant administration can produce severe hyperkalemia and should be avoided.

Potassium-sparing diuretic can increase the risk of hyperkalemia. Frequent monitoring of serum potassium is recommended if concomitant use is indicated.

Potassium-sparing diuretics with ACE inhibitors increase risk of hyperkalemia. Use with caution.

May cause significant increase in serum potassium. Should only be given for documented hypokalemia and with caution due to risk of hyperkalemia.

Triamterene may raise blood glucose levels; for adult-onset diabetes, dosage adjustments of hypoglycemic agents may be necessary during and/or after therapy; concurrent use with chlorpropamide may increase the risk of severe hyponatremia.

Potassium-sparing diuretic may lead to significant increases in serum potassium. Avoid in heart failure patients.

Potassium-sparing diuretic may lead to significant increases in serum potassium when used with enalapril.

Potassium-sparing diuretic; enalapril attenuates diuretic-induced potassium loss, increasing hyperkalemia risk.

Antifolate agent that directly inhibits dihydrofolate reductase, decreasing formation of active folate derivatives.

Potassium-sparing diuretic that can increase risk of hyperkalemia when used with fosinopril. Requires caution and frequent monitoring of serum potassium levels.

Acute renal failure has been reported in subjects when indomethacin was given with triamterene. Caution is advised.

Potassium-sparing diuretic can increase risk of hyperkalemia when used with lisinopril; requires frequent monitoring of serum potassium.

Potassium-sparing diuretic may lead to significant hyperkalemia when used with lisinopril which attenuates potassium loss.

Diuretic-induced sodium loss may reduce renal clearance of lithium and increase serum lithium levels with risk of lithium toxicity. Serum lithium levels should be monitored closely.

Concomitant use may lead to increases in serum potassium, which can be serious.

Most contain substantial amounts of potassium; may promote serum potassium accumulation and hyperkalemia when used with triamterene, especially in renal insufficiency.

Increased risk of hyperkalemia when potassium-sparing agents like triamterene are used with ACE inhibitors.

Potassium-sparing diuretic may lead to increases in serum potassium. Monitoring of serum potassium is advisable.

May promote serum potassium accumulation and result in hyperkalemia due to potassium-sparing nature of triamterene, especially in patients with renal insufficiency.

Risk of hyperkalemia. Perindopril may increase serum potassium by decreasing aldosterone production.

Potassium-containing agents given with triamterene promote serum potassium accumulation and may result in hyperkalemia, especially in patients with renal insufficiency.

Potassium-sparing diuretic increases risk of hyperkalemia. Frequent monitoring of serum potassium recommended if concomitant use indicated.

May lead to increased serum potassium levels. Monitor potassium levels during concomitant use.

Increased risk of severe and potentially fatal hyperkalemia when potassium chloride solution is administered.

Potassium-sparing diuretic increases risk of hyperkalemia when used with trandolapril; requires caution and appropriate serum potassium monitoring.

Potassium-sparing diuretic may lead to increases in serum potassium and in heart failure patients, increases in serum creatinine. Monitoring of serum potassium is advisable.

Potassium-sparing diuretic may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine when used with valsartan.

Coadministration resulted in higher plasma amantadine concentration; monitor amantadine levels.

Coadministration resulted in higher plasma amantadine concentration; monitor amantadine levels.

Potassium-sparing diuretic that may increase serum potassium when combined with valsartan. Monitor serum potassium levels.

Increased risk of hyperkalemia. Monitor serum potassium frequently during concomitant use.

Potassium-sparing diuretic may lead to significant increases in serum potassium when combined with enalapril. Avoid in heart failure patients.

Potassium-sparing diuretic may lead to significant increases in serum potassium when used concomitantly with enalaprilat. Use with caution and monitor serum potassium frequently.

Potassium-sparing diuretic that can increase risk of hyperkalemia when combined with fosinopril. Serum potassium should be monitored frequently.

Potassium-sparing diuretic may increase risk of hyperkalemia when used with fosinopril sodium and hydrochlorothiazide; requires monitoring of serum potassium.

Potassium-sparing diuretic may increase risk of hyperkalemia when used with CLINIMIX E due to its potassium content; administer with caution.

Cationic drug eliminated by renal tubular secretion with potential for interaction with metformin by competing for common renal tubular transport systems.

Potassium-sparing diuretic may increase risk of hyperkalemia when used concomitantly with moexipril. Requires caution and monitoring of serum potassium levels.

Effects of non-depolarizing skeletal muscle relaxants may be potentiated when given with triamterene.

Effects of other diuretics may be potentiated when given with triamterene.

May decrease plasma folate levels.

Potassium-sparing diuretic may increase serum potassium when used with quinapril. Use with caution and monitor serum potassium appropriately.

Effects of preanesthetic and anesthetic agents may be potentiated when given with triamterene.

Potassium-sparing diuretic that increases risk of hyperkalemia when used with ACE inhibitors. Use with caution and monitor serum potassium.

Potential for drug-drug interaction due to possible competition for active tubular secretion via base-secreting system.

The following agents, given together with triamterene, may promote serum potassium accumulation and possibly result in hyperkalemia because of the potassium-sparing nature of triamterene, especially in patients with renal insufficiency: blood from blood bank (may contain up to 30 mEq of potassium per liter of plasma or up to 65 mEq per liter of whole blood when stored for more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per liter); potassium-containing medications (such as parenteral penicillin G potassium); salt substitutes (most contain substantial amounts of potassium).